Risk factors for residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a systematic review and meta-analysis

Ke, Yujie; Ma, Xin; Jing, Yuanyuan; Diao, Tongxiang; Yu, Lisheng

doi:10.1007/s00405-022-07288-9

Cited by 23 publications

(32 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there was no difference between the groups in terms of RD duration. We also observed a positive correlation between RD and BPPV duration and DHI similar to the literature (18,21).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

The Effect of Repositioning Maneuver Applied with the TRV Chair on Residual Dizziness after Benign Paroxysmal Positional Vertigo

Söylemez¹,

BİNAY>²,

Karakoc³

et al. 2023

Otol Neurotol

View full text Add to dashboard Cite

Objective This study aims to investigate the effect of TRV chair on residual dizziness (RD) after idiopathic posterior semicircular canal benign paroxysmal positional vertigo (BPPV) successfully treated with canalith repositioning maneuver (CRM). Study Design Prospective case–control study. Setting Hospital. Patients Thirty-three patients with posterior canal BPPV were included in the study. These patients were divided into two identical groups. CRM was applied to the first group with a TRV chair (TRV group) and manually to the second group (manual group). Interventions Dizziness Handicap Inventory (DHI), Beck Anxiety Inventory (BAI), and video head impulse test were applied to the patients. Patients in both groups were asked to report the RD developed after successful CRM daily by visual analog scale (VAS). Results The TRV group’s first-day RD rate was 94.1% with VAS, and the RD duration was 2.47 ± 1.77 (0–7) days. The manual group’s first-day RD rate was 100%, and the RD duration was 3.38 ± 1.70 (1–7) days. There was no difference between the groups in terms of RD duration (p > 0.05). Mean RD severity and severity in the first 3 days were lower in the TRV group compared with the manual group (p < 0.05). There was no difference between the groups on other days (p > 0.05). In addition, there was a positive correlation between RD and DHI and BPPV duration (p < 0.05). Conclusion RD is a multifactorial symptom associated with how the repositioning maneuver is performed, BPPV duration, and DHI. Performing the repositioning maneuver with the TRV chair can reduce the severity of RD.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Although the negative effect of RD after successful CRM is thought to be less than BPPV, it can cause falls, activity restrictions, and social and economic burdens, especially in elderly individuals (18). Prolonged RD may cause a perception of chronic illness in individuals and affect the quality of life of these.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Repositioning Maneuver Applied with the TRV Chair on Residual Dizziness after Benign Paroxysmal Positional Vertigo

Söylemez¹,

BİNAY>²,

Karakoc³

et al. 2023

Otol Neurotol

View full text Add to dashboard Cite

show abstract

“…Previous studies have revealed that the total DHI scores, especially DHI-F and DHI-E scores at the baseline, are significantly higher in the RD group than in the non-RD group. This indicates that patients with BPPV who have their life and emotional state more greatly affected before treatment are more likely to develop RD (37,38). Fu et al (39) found that patients with a DHI score of >30 had a nearly 2-fold higher risk of RD compared to those with a DHI score of ≤30.…”

Section: Discussionmentioning

confidence: 99%

Effect of the serum 25-hydroxyvitamin D level on risk for short-term residual dizziness after successful repositioning in benign paroxysmal positional vertigo stratified by sex and onset age

Jiang

Bai

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveA low serum 25-hydroxyvitamin D (25(OH)D) level is relevant to both the occurrence and recurrence of benign paroxysmal positional vertigo (BPPV). However, whether it also contributes to residual dizziness (RD) after successful repositioning maneuvers is unknown. Therefore, this study aimed to explore the correlation between the serum 25(OH)D level and short-term RD severity in patients with BPPV after successful repositioning maneuvers.MethodsIn total, 251 patients with BPPV after successful repositioning were enrolled and prospectively followed up for 1 week (W1). Serum 25(OH)D values were detected by chemiluminescence immunoassay at enrollment (W0). In addition, we explored the relationship between 25(OH)D values at baseline and RD severity at W1 in different subgroups stratified by sex and onset age (early-onset, ≤50 years; late-onset, >50 years).ResultsThe serum 25(OH)D level of female patients was significantly lower than that of male patients (15.9 ± 6.8 vs. 19.8 ± 6.6 ng/ml, p < 0.001). Its level also decreased in early-onset patients compared to late-onset ones (15.3 ± 5.9 vs. 18.0 ± 7.3 ng/ml, p = 0.003). In addition, early-onset female patients had lower 25(OH)D values than late-onset female patients (14.0 ± 5.5 vs. 17.1 ± 7.2 ng/ml, p = 0.004). However, this difference was not observed between early- and late-onset male patients. Among early-onset female patients, the 25(OH)D values of the moderate-to-severe RD group were lower than those of the minor or no RD group (10.9 ± 3.3 vs. 14.7 ± 5.7 vs. 15.0 ± 5.9 ng/ml, p = 0.046). Multivariate analysis found that decreased 25(OH)D values were related to the occurrence of moderate-to-severe RD in early-onset female patients (OR = 0.801; p = 0.022). This effect did not exist in late-onset female or male patients with BPPV.ConclusionsAge and sex differences in serum 25(OH)D levels exist in patients with BPPV. A decreased 25(OH)D level in early-onset female patients may increase the odds of moderate-to-severe RD 1 week after successful repositioning maneuvers.

show abstract

“…Доброякісний характер вертиго при ДППВ зумовлений високою вірогідністю спонтанної регресії, тривалість якої у 30-50% випадках не перевищує 1 міс; у частини хворих перебіг захворювання набуває безперервно рецидивую чого перебігу [6]. Вірогідність рецидиву запаморочення при ДППВ зростає з віком (відносний ризик (ВР) 4,17; 95% довір чий інтервал (ДI) 2,13-6,21; р=0,0001), при наявності супут ньої тривоги (ВР 9,58; 95% ДІ 6,32-14,52; р=0,0001), остеопенії (ВР 4,40; 95% ДІ 2,17-8,96; р=0,0001), ДППВ в анамнезі (ВР 1,79; 95% ДІ 1,06-3,04; р=0,03) [7]. Коморбідна артеріальна гіпертензія (ВР 2,61; 95% ДI 1,22-5,59; р=0,01), цукровий діабет (ВР 2,62; 95% ДI 1,25-5,48; р=0,01), гіперліпідемія (ВР 1,60; 95% ДI 1,23-2,09; р=0,0006) асоційовані зі зростанням ризику рецидиву ДППВ [8].…”

Section: клінічні проявиunclassified

Фармакотерапія Вертиго: Сучасні Дані Доказової Медицини

2022

UMJ

View full text Add to dashboard Cite

show abstract

Risk factors for residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a systematic review and meta-analysis

Cited by 23 publications

References 61 publications

The Effect of Repositioning Maneuver Applied with the TRV Chair on Residual Dizziness after Benign Paroxysmal Positional Vertigo

The Effect of Repositioning Maneuver Applied with the TRV Chair on Residual Dizziness after Benign Paroxysmal Positional Vertigo

Effect of the serum 25-hydroxyvitamin D level on risk for short-term residual dizziness after successful repositioning in benign paroxysmal positional vertigo stratified by sex and onset age

Фармакотерапія Вертиго: Сучасні Дані Доказової Медицини

Contact Info

Product

Resources

About